Replies to post #17095 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Interchangeable Humira FoB for US market is badly needed:



Source: Barron's (http://www.barrons.com/articles/as-drug-prices-fall-these-stocks-could-rise-1492230223 ).

[rwwine]

Hi Dew, I see this much more valuable than the 40 mg dose approval of M-Copax and the reason I'm still in this venture. Do you see MNTA working a deal for Humira alone or the entire company itself? The market cap is pretty low in my opinion and honestly see a complete buyout taking place.

Thanks in advance.

[DewDiligence]

MNTA bold prediction:

https://twitter.com/DewDiligence/status/879807089010515968 (scan up)

[DewDiligence]

B-I starts switching study for Humira FoB:

http://www.businesswire.com/news/home/20170727005789/en/Boehringer-Ingelheim-starts-clinical-study-interchangeability-adalimumab

The point of a switching study is to seek FDA interchangeable status.